4.72
0.13 (2.83%)
| Previous Close | 4.59 |
| Volume | 756,806 |
| Price / Sales | 9.69 |
| Price / Book | 6.56 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Nuvation Bio Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.1 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.22 |
Select this tab to load the latest available analysis.
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 62.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Jun 2026 | 25,954,439 |
| Omega Fund Management, Llc | 30 Jun 2026 | 8,081,089 |
| Laurion Capital Management Lp | 30 Sep 2026 | 7,697,272 |
| Duquesne Family Office Llc | 30 Jun 2026 | 4,539,800 |
| Tang Capital Management Llc | 30 Jun 2026 | 3,299,557 |
| Redmile Group, Llc | 30 Jun 2026 | 3,031,009 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |